Menu Back toDIA DIRECT: Study and Data Integrity Considerations for Clinical Trials Impacted by COVID-19

DIA DIRECT: Study and Data Integrity Considerations for Clinical Trials Impacted by COVID-19

The fourth in our series of DIA DIRECT: COVID-19 Webinars!


Overview

Brought to you with the support of DIA Knowledge Brigade.


This on demand webinar recording is approximately 1 hour long.


The ongoing COVID-19 pandemic is creating unprecedented challenges in conducting clinical trials and assuring data integrity. In response to these challenges, a COVID-19 pharmaceutical industry biostatistics working group was formed to tackle emerging issues in ongoing clinical trials.

Join us for the fourth in our DIA DIRECT COVID-19 Webinar Series, to learn more about:

  • Risk assessment and mitigation strategies for trial integrity and interpretability
  • Assessing treatment effects and methodology considerations including missing data and implications on analyses, documentation, and communication

New! Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 Pandemic

Read Paper

DIA DIRECT: COVID-19 Webinar Series

Back to DIA Now In Focus: COVID-19


Continuing Education Credits are not offered for this event.

Contact us

Zoom Technical Support

Send Email